Project/scholarship details
- Project/scholarship ID
115290
- Reference
PTDC/SAU-FAR/115290/2009
- FundRef URI
- Funder
FCT - Fundação para a Ciência e a Tecnologia, I.P.
- Funder's country
Portugal
- Funding program
3599-PPCDT
- Funding amount
168,200.00 €
- Start date
2010-12-22
- End date
2014-09-21
Documents
Resistance to antibody neutralization in HIV-2 infection occurs in late stage d...
Marcelino, José Maria; Borrego, Pedro; Nilsson, Charlotta; Família, Carlos; Barroso, Helena; Maltez, Fernando; Doroana, Manuela; Antunes, FranciscoThis is a non-final version of an article published in final form in AIDS. 28 November 2012 - Volume 26 - Issue 18 - p 2275–2284; Objectives: To characterize the nature and dynamics of the neutralizing antibody (NAb) response and escape in chronically HIV-2 infected patients.; Methods: Twenty-eight chronically infected adults were studied over a period of 1-4 years. The neutralizing activity of plasma IgG antib...
An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and ...
Borrego, Pedro; Calado, Rita; Marcelino, José M.; Pereira, Patrícia; Quintas, Alexandre; Barroso, Helena; Taveira, Nuno"Objectives: To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on ancestral envelope sequences. Methods: HIV-2/simian immunodeficiency virus (SIV) ancestral transmembrane protein sequences were reconstructed and ancestral peptides were derived from the helical region 2 (HR2). The activity of one ancestral peptide (named P3) was examined against a panel of HIV-1 and HIV-2 primary isolates in TZM...
Evolution of the human immunodeficiency virus type 2 envelope in the first year...
Rocha, Cheila; Calado, Rita; Borrego, Pedro; Marcelino, José Maria; Bártolo, Inês; Rosado, Lino; Cavaco-Silva, Patrícia; Perpétua, Gomes"Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and ...
Envelope C2-V3-C3-specific antibodies from HIV-1 infected patients from Angola ...
Calado, R.; Duarte, J.; Diniz, A. R.; Borrego, P.; Marcelino, J. M.; Wilton, J.; Bartólo, I.; Clemente, S.; Taveira, N.Poster presented at the 2015 Keystone Symposia Conference X5: HIV Vaccines. Banff, Alberta, Canada, 22-27 March 2015; "Development of immunogens that induce broadly neutralizing antibodies (bNAbs) is a major goal in HIV-1 vaccine field. Recently, we found that bNAbs can be elicited in Balb/c mice against HIV-2 by using a prime-boost vaccination strategy combining recombinant Vaccinia virus expressing a truncate...
Evaluation of an in-house molecular HIV-1 test to assess mother-to-child HIV-1 ...
Martin, F.; Palladino, C.; Mateus, R.; Clemente, S.; Gomes, P.; Taveira, N.Poster presented at the 17th Annual International Meeting of the Institute of Human Virology. Baltimore, 27-30 September 2015; "Mother-to-child-transmission (MTCT) rate has decreased sharply in recent years in most of the sub-Saharan Africa, however 220,000 children acquired HIV-1 in 2014. PCR detection of proviral DNA is the most sensitive method for early infant diagnosis (EID) of HIV-1 infection. Commercial ...
Report
Embed
<script type="text/javascript">
<!--
document.write('<div id="rcaap-widget"></div>');
document.write('<script type="text/javascript" src="https://www.rcaap.pt/snippet?resource=documents&project=FCT%2F3599-PPCDT%2F115290&fields=id,titles,creators,issueDate,link,descriptions"></script>');
-->
</script>